Payment overview · 2025
General Payments
$109,829.02
218 reported records · 26 companies
Healthcare provider profile · identity verified
Misha Denham, DO
Allopathic & Osteopathic Physicians|Internal Medicine|Endocrinology, Diabetes & Metabolism · CORAL GABLES, FL · NPI 1689659096
Verified facts
What the public records show
CMS Open Payments records show Misha Denham, DO received $109,829.02 in general payments during 2025 across 218 reported records.
Lilly USA, LLC accounted for 75.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 32 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Ozempic, Rybelsus, Xyosted.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 259 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Prolia by this doctor in 2024.
Antares Pharma, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XYOSTED as an associated drug or biological on 18015 records involving 7619 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Xyosted by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 197 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 197 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 287 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Fiasp as an associated drug or biological on 15 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Fiasp by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 260 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Rybelsus by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Tresiba as an associated drug or biological on 415 records involving 264 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Tresiba by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $83,004.03 | 75.6% | 137 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $18,077.81 | 16.5% | 32 | 2025 |
| Verity Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $7,810.29 | 7.1% | 7 | 2025 |
| Mannkind Corporation | Unresolved — no canonical attribution shown | $178.08 | 0.2% | 4 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $79.86 | 0.1% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $64.05 | 0.1% | 3 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $63.52 | 0.1% | 3 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $58.74 | 0.1% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $51.84 | 0.1% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $40.73 | 0.0% | 2 | 2025 |
| Ascendis Pharma Endocrinology Inc | Unresolved — no canonical attribution shown | $39.57 | 0.0% | 2 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $37.71 | 0.0% | 2 | 2025 |
| IBSA Pharma Inc. | Unresolved — no canonical attribution shown | $37.54 | 0.0% | 2 | 2025 |
| VIVUS LLC | Unresolved — no canonical attribution shown | $37.25 | 0.0% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $34.53 | 0.0% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $22.79 | 0.0% | 1 | 2025 |
| RECORDATI_RARE_DISEASES_INC. | Unresolved — no canonical attribution shown | $20.96 | 0.0% | 1 | 2025 |
| Sequel Med Tech, LLC | Unresolved — no canonical attribution shown | $20.85 | 0.0% | 1 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.70 | 0.0% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $20.32 | 0.0% | 1 | 2025 |
| Alvogen Inc | Unresolved — no canonical attribution shown | $19.99 | 0.0% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $19.84 | 0.0% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $19.79 | 0.0% | 1 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $18.93 | 0.0% | 1 | 2025 |
| Medicure Pharma Inc. | Unresolved — no canonical attribution shown | $14.72 | 0.0% | 1 | 2025 |
| Rhythm Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.58 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $94,122.19 | 99 |
| Travel and Lodging | $6,386.07 | 39 |
| Honoraria | $6,000.00 | 2 |
| Food and Beverage | $3,296.72 | 77 |
| Education | $24.04 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $80,054.10 | 129 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $17,939.07 | 29 | 2025 |
Source payment records
|
|||||
| Tlando Normalized: tlando |
Drug | Verity Pharmaceuticals Inc. | $7,810.29 | 7 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $4,358.50 | 9 | 2025 |
Source payment records
|
|||||
| AFREZZA Normalized: afrezza |
Drug | Mannkind Corporation | $178.08 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $64.05 | 3 | 2025 |
Source payment records
|
|||||
| CRENESSITY Normalized: crenessity |
Drug | Neurocrine BioSciences, Inc. | $63.52 | 3 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $58.74 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $51.84 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $40.73 | 2 | 2025 |
Source payment records
|
|||||
| RECORLEV Normalized: recorlev |
Drug | Xeris Pharmaceuticals, Inc. | $40.00 | 2 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $39.86 | 2 | 2025 |
Source payment records
|
|||||
| Yorvipath Normalized: yorvipath |
Drug | Ascendis Pharma Endocrinology Inc | $39.57 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $39.36 | 2 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $37.71 | 2 | 2025 |
Source payment records
|
|||||
| Flector Normalized: flector |
Drug | IBSA Pharma Inc. | $37.54 | 2 | 2025 |
Source payment records
|
|||||
| Licart Normalized: licart |
Drug | IBSA Pharma Inc. | $37.54 | 2 | 2025 |
Source payment records
|
|||||
| Tirosint Normalized: tirosint |
Drug | IBSA Pharma Inc. | $37.54 | 2 | 2025 |
Source payment records
|
|||||
| PANCREAZE Normalized: pancreaze |
Drug | VIVUS LLC | $37.25 | 2 | 2025 |
Source payment records
|
|||||
| TEPEZZA Normalized: tepezza |
Biological | Amgen Inc. | $34.53 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $33.49 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $22.79 | 1 | 2025 |
Source payment records
|
|||||
| ISTURISA Normalized: isturisa |
Drug | RECORDATI_RARE_DISEASES_INC. | $20.96 | 1 | 2025 |
Source payment records
|
|||||
| TWIIST Normalized: twiist |
Device | Sequel Med Tech, LLC | $20.85 | 1 | 2025 |
Source payment records
|
|||||
| AZMIRO Normalized: azmiro |
Drug | Azurity Pharmaceuticals, Inc. | $20.70 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $20.32 | 1 | 2025 |
Source payment records
|
|||||
| TERIPARATIDE Normalized: teriparatide |
Drug | Alvogen Inc | $19.99 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $19.84 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $19.79 | 1 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $18.93 | 1 | 2025 |
Source payment records
|
|||||
| Zypitamag Normalized: zypitamag |
Drug | Medicure Pharma Inc. | $14.72 | 1 | 2025 |
Source payment records
|
|||||
| IMCIVREE Normalized: imcivree |
Drug | Rhythm Pharmaceuticals, Inc. | $14.58 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 197 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 287 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 260 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 58 | exact normalized | Medicare Part D |
| XYOSTED xyosted |
2025 | Xyosted | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
43 | 17 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
259 | 67 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Antares Pharma, Inc. Exact reporting entity; no affiliate inference |
2025 | XYOSTED open payments reported associated product |
CMS Open Payments — General Payments 18015 supporting records · 7619 recipient NPIs · example record 1235880452 |
Xyosted · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
197 | 48 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
197 | 48 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
287 | 60 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
64 | 20 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Fiasp open payments reported associated product |
CMS Open Payments — General Payments 15 supporting records · 15 recipient NPIs · example record 1188262936 |
Fiasp · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
260 | 60 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
58 | 19 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Tresiba open payments reported associated product |
CMS Open Payments — General Payments 415 supporting records · 264 recipient NPIs · example record 1188130328 |
Tresiba · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 629 | 167 |
| Metformin Hcl | Metformin Hcl | 300 | 94 |
| Mounjaro | Tirzepatide | 287 | 60 |
| Atorvastatin Calcium | Atorvastatin Calcium | 284 | 95 |
| Ozempic | Semaglutide | 260 | 60 |
| Synthroid | Levothyroxine Sodium | 259 | 67 |
| Liothyronine Sodium | Liothyronine Sodium | 245 | 76 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 244 | 84 |
| Losartan Potassium | Losartan Potassium | 228 | 79 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 224 | 84 |
| Jardiance | Empagliflozin | 197 | 48 |
| Tresiba Flextouch U-100 | Insulin Degludec | 197 | 70 |
| Veo Insulin Syringe | Syringe And Needle,insulin,1ml | 172 | 80 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 171 | 74 |
| Lisinopril | Lisinopril | 158 | 51 |
| Amlodipine Besylate | Amlodipine Besylate | 150 | 49 |
| Pantoprazole Sodium | Pantoprazole Sodium | 114 | 42 |
| Metoprolol Succinate | Metoprolol Succinate | 106 | 32 |
| Vascepa | Icosapent Ethyl | 104 | 27 |
| Gabapentin | Gabapentin | 101 | 36 |
| Ezetimibe | Ezetimibe | 96 | 33 |
| Alprazolam | Alprazolam | 95 | 18 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 92 | 24 |
| Omeprazole | Omeprazole | 89 | 32 |
| Testosterone Cypionate | Testosterone Cypionate | 89 | 21 |
| Pioglitazone Hcl | Pioglitazone Hcl | 78 | 25 |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 75 | 45 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 75 | 25 |
| Eliquis | Apixaban | 72 | 21 |
| Clonazepam | Clonazepam | 66 | 16 |
| Novolog Flexpen | Insulin Aspart | 66 | 24 |
| Simvastatin | Simvastatin | 66 | 23 |
| Trulicity | Dulaglutide | 64 | 20 |
| Montelukast Sodium | Montelukast Sodium | 61 | 19 |
| Hydrocortisone | Hydrocortisone | 59 | 12 |
| Farxiga | Dapagliflozin Propanediol | 58 | 18 |
| Rybelsus | Semaglutide | 58 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 57 | 19 |
| Allopurinol | Allopurinol | 56 | 18 |
| Glimepiride | Glimepiride | 53 | 17 |
| Humalog Kwikpen U-100 | Insulin Lispro | 53 | 26 |
| Clopidogrel | Clopidogrel Bisulfate | 52 | 19 |
| Tamsulosin Hcl | Tamsulosin Hcl | 51 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 50 | 16 |
| Pregabalin | Pregabalin | 50 | suppressed |
| Carvedilol | Carvedilol | 49 | 19 |
| Famotidine | Famotidine | 49 | 18 |
| Potassium Chloride | Potassium Chloride | 49 | 15 |
| Tradjenta | Linagliptin | 46 | 14 |
| Januvia | Sitagliptin Phosphate | 44 | 18 |
| Metformin Hcl Er | Metformin Hcl | 44 | 16 |
| Linzess | Linaclotide | 43 | 17 |
| Fenofibrate | Fenofibrate Nanocrystallized | 42 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 42 | 15 |
| Spironolactone | Spironolactone | 41 | 17 |
| Calcitriol | Calcitriol | 40 | suppressed |
| Testosterone | Testosterone | 39 | suppressed |
| Irbesartan | Irbesartan | 37 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 37 | 14 |
| Atenolol | Atenolol | 36 | suppressed |
| Estradiol | Estradiol | 36 | 12 |
| Alendronate Sodium | Alendronate Sodium | 35 | 11 |
| Furosemide | Furosemide | 35 | 16 |
| Glipizide | Glipizide | 35 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 35 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 34 | 11 |
| Progesterone | Progesterone, Micronized | 33 | suppressed |
| Telmisartan | Telmisartan | 33 | 11 |
| Valsartan | Valsartan | 33 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 32 | 15 |
| Xyosted | Testosterone Enanthate | 32 | suppressed |
| Folic Acid | Folic Acid | 29 | 12 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 29 | suppressed |
| Fluconazole | Fluconazole | 28 | 15 |
| Icosapent Ethyl | Icosapent Ethyl | 28 | 13 |
| Prednisone | Prednisone | 28 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 27 | suppressed |
| Nifedipine Er | Nifedipine | 27 | 12 |
| Nateglinide | Nateglinide | 26 | suppressed |
| Temazepam | Temazepam | 26 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 26 | 13 |
| Xarelto | Rivaroxaban | 26 | suppressed |
| Creon | Lipase/Protease/Amylase | 25 | suppressed |
| Repatha Sureclick | Evolocumab | 25 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 24 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 24 | 12 |
| Humalog | Insulin Lispro | 24 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 23 | 14 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 23 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 23 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 23 | suppressed |
| Glipizide Er | Glipizide | 22 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 22 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Baqsimi | Glucagon | 20 | 12 |
| Diazepam | Diazepam | 20 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 20 | 11 |
| Tresiba | Insulin Degludec | 20 | suppressed |
| Ulticare Pen Needle | Pen Needle, Diabetic | 20 | 12 |
| Methimazole | Methimazole | 19 | suppressed |
| Sucralfate | Sucralfate | 19 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 19 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 18 | suppressed |
| Fenofibrate | Fenofibrate | 18 | suppressed |
| Anastrozole | Anastrozole | 17 | suppressed |
| Azithromycin | Azithromycin | 17 | 12 |
| Finasteride | Finasteride | 17 | suppressed |
| Lactulose | Lactulose | 17 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 16 | suppressed |
| Lyumjev Kwikpen U-100 | Insulin Lispro-Aabc | 16 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 16 | suppressed |
| Chlorthalidone | Chlorthalidone | 15 | suppressed |
| Cialis | Tadalafil | 15 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 15 | suppressed |
| Lorazepam | Lorazepam | 15 | suppressed |
| Novofine 32 | Pen Needle, Diabetic | 15 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 15 | suppressed |
| Bumetanide | Bumetanide | 14 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 14 | suppressed |
| Invokana | Canagliflozin | 14 | suppressed |
| Prolia | Denosumab | 14 | suppressed |
| Safetyglide Insulin Syringe | Syringe,needle,insuln,safe,1ml | 14 | suppressed |
| Fiasp | Insulin Aspart (Niacinamide) | 13 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 13 | suppressed |
| Levofloxacin | Levofloxacin | 13 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 13 | suppressed |
| Baclofen | Baclofen | 12 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Nadolol | Nadolol | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 11 | suppressed |
| Insulin Syringe | Syring-Needl,disp,insul,0.3 Ml | 11 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $109,829.02 · 218 records | Lilly USA, LLC | AFREZZA, AZMIRO, CRENESSITY, Dexcom G6 Transmitter, Flector, GVOKE HYPOPEN, IMCIVREE, ISTURISA, JARDIANCE, Kerendia, Korlym, LEQVIO, Licart, MOUNJARO, Ozempic, PANCREAZE, RECORLEV, REZDIFFRA, Rybelsus, TEPEZZA, TERIPARATIDE, TWIIST, TZIELD, Tirosint, Tlando, UBRELVY, Wegovy, XYOSTED, Yorvipath, ZENPEP, ZEPBOUND, Zypitamag | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error